Filozad 60 mg powder for solution for injection Vial

Filozad 60 mg Powder for Solution for Injection is an essential medication used in the treatment of specific types of cancer. This product is formulated as a lyophilized powder in a sterile vial, designed for reconstitution and subsequent intravenous administration. As a potent antineoplastic agent, Filozad works to inhibit the proliferation of cancer cells, playing a crucial role in chemotherapy regimens.

For comprehensive information on Filozad 60 mg, please refer to trusted pharmaceutical resources such as Nahdi Online, , and , where you can find product details and potentially visual guides.

Product Details

Filozad 60 mg Powder for Solution for Injection contains Bendamustine Hydrochloride as its active pharmaceutical ingredient. It is presented in a sterile vial, intended for single-use, providing a precise dosage for oncology treatments. This medication is a prescription-only product and must be administered under the direct supervision of a healthcare professional experienced in the administration of chemotherapeutic agents. The packaging ensures the stability and integrity of the sterile powder until the point of use, facilitating safe and effective treatment.

Benefits of Use

• Effective in treating certain types of cancer, including Chronic Lymphocytic Leukemia (CLL) and indolent Non-Hodgkin's Lymphomas.
• Works by damaging the DNA within cancer cells, preventing their growth and division.
• Administered intravenously for direct systemic action, targeting malignant cells throughout the body.
• Part of established chemotherapy protocols, aiming to achieve remission or control disease progression.

How to Use

1. Filozad 60 mg Powder for Solution for Injection must be prepared and administered by a trained healthcare professional in a clinical setting.
2. The powder is reconstituted using the specified volume of sterile water for injection, following aseptic techniques.
3. The reconstituted solution is then further diluted with an appropriate intravenous solution (e.g., 0.9% Sodium Chloride Injection) to the required concentration.
4. The diluted solution is administered as an intravenous infusion over a period typically ranging from 30 to 60 minutes, as prescribed by the physician.
5. The dosage and treatment schedule are individualized based on the patient's specific cancer type, stage, body surface area, and tolerance to the medication.
6. Do not administer if the solution appears cloudy, discolored, or contains particulate matter after reconstitution and dilution.

Caution & Warnings

• Always administer under the strict supervision of an oncologist or a physician experienced in chemotherapy.
• Filozad can cause severe myelosuppression, including neutropenia, thrombocytopenia, and anemia, which may lead to life-threatening infections and bleeding. Regular complete blood count monitoring is essential.
• Severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Seek immediate medical attention for any new or worsening skin rash.
• Patients should be monitored for signs of tumor lysis syndrome, especially at the start of treatment, and managed accordingly.
• May cause gastrointestinal side effects such as nausea, vomiting, diarrhea, and mucositis. Appropriate supportive care should be provided.
• Filozad is genotoxic and teratogenic. Women of childbearing potential and men should use effective contraception during and for a specified period after treatment.
• Avoid vaccination with live vaccines during treatment with Filozad.
• Hypersensitivity reactions, including anaphylaxis, can occur. Emergency equipment and personnel should be readily available.

Ingredients

• Active Ingredient: Bendamustine Hydrochloride 60 mg
• Excipients: Mannitol